Verseon Stock Price, News & Analysis (LON:VSN)

GBX 120 0.00 (0.00 %)
(As of 01/19/2018 04:00 PM ET)
Previous CloseGBX 120
Today's RangeGBX 123 - GBX 123
52-Week RangeGBX 120 - GBX 165
Volume2,510 shs
Average Volume449 shs
Market Capitalization£150.64 million
P/E Ratio-1,333.33
Dividend YieldN/A
BetaN/A

About Verseon (LON:VSN)

Verseon Corporation is a pharmaceutical company. The Company's platform models interactions between a protein and a drug molecule with precision sufficient for designing drug candidates. The Company operates through the pharmaceutical research segment. The Company uses its drug discovery technology to develop a portfolio of programs targeting disease areas consisting of anti-coagulation, diabetic macular edema (DMA) and oncology. The Company's platform generates a range of drug-like, synthesizable compounds, which are then computationally tested against a disease-causing protein to identify the binders, the drug candidates that could potentially treat the disease. These computationally designed candidates are synthesized and sent through a series of disease specific in vitro and in vivo tests to identify the candidates for clinical testing in humans.

Receive VSN News and Ratings via Email

Sign-up to receive the latest news and ratings for VSN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolLON:VSN
CUSIPN/A
Phone+1-510-2259000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-1333.33333333333
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.09)
Net IncomeN/A
Net MarginsN/A
Return on Equity-31.03%
Return on Assets-27.17%

Miscellaneous

EmployeesN/A
Outstanding Shares151,430,000

Verseon (LON:VSN) Frequently Asked Questions

What is Verseon's stock symbol?

Verseon trades on the London Stock Exchange (LON) under the ticker symbol "VSN."

Who are some of Verseon's key competitors?

Who are Verseon's key executives?

Verseon's management team includes the folowing people:

  • Adityo Prakash, Chief Executive Officer, Founder, Executive Director
  • Eniko Fodor, Founder, Chief Financial Officer, Chief Operating Officer, Executive Director
  • David Kita, Founder, Vice President - Research & Development
  • Anirban Datta, Director - Discovery Biology
  • Kevin Short, Director - Discovery Programs
  • David Williams, Director - R&D
  • Thomas A. Hecht, Non-Executive Chairman of the Board
  • Alastair Andrew Bertram Cade, Non-Executive Director
  • Grover T. Wickersham, Non-Executive Director (Age 67)

How do I buy Verseon stock?

Shares of Verseon and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Verseon's stock price today?

One share of Verseon stock can currently be purchased for approximately GBX 120.

How big of a company is Verseon?

Verseon has a market capitalization of £150.64 million.

How can I contact Verseon?

Verseon's mailing address is 48820 Kato Rd Ste 100B, FREMONT, CA 94538-7323, United States. The company can be reached via phone at +1-510-2259000.


MarketBeat Community Rating for Verseon (VSN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  79
MarketBeat's community ratings are surveys of what our community members think about Verseon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Verseon (LON:VSN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A

Verseon (LON:VSN) Consensus Price Target History

Price Target History for Verseon (LON:VSN)

Verseon (LON:VSN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
7/4/2017Cenkos SecuritiesReiterated RatingBuyView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Earnings History for Verseon (LON:VSN)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Verseon (LON:VSN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Verseon (LON:VSN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Verseon (LON VSN) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Verseon (LON:VSN)

Verseon (LON VSN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2016Fodor,EnikoInsiderBuy6,000GBX 161£9,660
(Data available from 1/1/2013 forward)

Headlines

Verseon (LON VSN) News Headlines

Source:
DateHeadline
A look at the trucks about to hit the Detroit Auto Show stage - The Globe and MailA look at the trucks about to hit the Detroit Auto Show stage - The Globe and Mail
www.theglobeandmail.com - January 12 at 10:25 AM
Verseon presents HAE program at Biotech Showcase - London South East (blog)Verseon presents HAE program at Biotech Showcase - London South East (blog)
www.lse.co.uk - January 11 at 4:39 PM
Biotechs uncork IPO plans on eve of new year - San Francisco Business TimesBiotechs uncork IPO plans on eve of new year - San Francisco Business Times
www.bizjournals.com - January 2 at 5:21 PM
Why JD.Com Inc(ADR) Stock Is the Amazon of China - Investorplace.comWhy JD.Com Inc(ADR) Stock Is the Amazon of China - Investorplace.com
investorplace.com - December 22 at 10:33 AM
FACBOX-Corporate alternative minimum tax threat hits pharma, techFACBOX-Corporate alternative minimum tax threat hits pharma, tech
www.cnbc.com - December 7 at 10:48 AM
REFILE-FACTBOX-Corporate alternative minimum tax threat hits pharma, techREFILE-FACTBOX-Corporate alternative minimum tax threat hits pharma, tech
www.cnbc.com - December 6 at 4:33 PM
Toblerone vs. Poundland: A Food Fight With Peaks and Troughs - New York TimesToblerone vs. Poundland: A Food Fight With Peaks and Troughs - New York Times
www.nytimes.com - December 5 at 12:05 PM
Jean-Claude Van Damme Plays Jean-Claude Van Damme, for Kicks - New York TimesJean-Claude Van Damme Plays Jean-Claude Van Damme, for Kicks - New York Times
www.nytimes.com - December 2 at 8:57 AM
More London Hot Clicks From Agatha Christie, Mel Brooks, Paddy Chayevsky via Ivo van Hove, and Mike Bartlett - HuffPostMore London Hot Clicks From Agatha Christie, Mel Brooks, Paddy Chayevsky via Ivo van Hove, and Mike Bartlett - HuffPost
www.huffingtonpost.com - November 16 at 6:59 AM
Verseon Presents Second Anticoagulation Candidate for Clinical Trials at AHA 2017Verseon Presents Second Anticoagulation Candidate for Clinical Trials at AHA 2017
finance.yahoo.com - November 16 at 6:58 AM
Peugeot Sets Sights on a Feat That Evaded Opel for Years: a ProfitPeugeot Sets Sights on a Feat That Evaded Opel for Years: a Profit
www.msn.com - November 9 at 9:41 AM
Verseon’s Novel Anticancer Agents for Multidrug Resistant Tumors Presented at BIO-Europe 2017Verseon’s Novel Anticancer Agents for Multidrug Resistant Tumors Presented at BIO-Europe 2017
finance.yahoo.com - November 9 at 9:41 AM
Calculating The Fair Value Of Verseon Corporation (AIM:VSN)Calculating The Fair Value Of Verseon Corporation (AIM:VSN)
finance.yahoo.com - November 9 at 9:41 AM
Verseon to Present Preclinical Data on Novel Anticancer Candidates for Use against Multidrug Resistant CancersVerseon to Present Preclinical Data on Novel Anticancer Candidates for Use against Multidrug Resistant Cancers
finance.yahoo.com - October 31 at 11:55 AM
Verseon Corporation (AIM:VSN): Is Now The Time To Bet On Healthcare?Verseon Corporation (AIM:VSN): Is Now The Time To Bet On Healthcare?
finance.yahoo.com - October 24 at 4:25 PM
Leading pharmaceutical executive Dr. Robert Karr joins Verseon’s Board of DirectorsLeading pharmaceutical executive Dr. Robert Karr joins Verseon’s Board of Directors
finance.yahoo.com - October 24 at 12:07 PM
Result of Special Meeting & Board Appointment - London South East (blog)Result of Special Meeting & Board Appointment - London South East (blog)
www.lse.co.uk - October 20 at 9:34 PM
Verseon Developing Oral Treatment for Hereditary AngioedemaVerseon Developing Oral Treatment for Hereditary Angioedema
finance.yahoo.com - October 3 at 2:45 PM
Verseon Corp (VSN) Scheduled to Post Earnings on TuesdayVerseon Corp (VSN) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - August 29 at 1:34 AM
Qualcomm vs. Apple – Investors Prep for War as Feud Escalates - Investorplace.comQualcomm vs. Apple – Investors Prep for War as Feud Escalates - Investorplace.com
investorplace.com - July 12 at 8:23 PM
Two Siblings, Both Toddlers, Die Overnight in the Bronx - New York TimesTwo Siblings, Both Toddlers, Die Overnight in the Bronx - New York Times
www.nytimes.com - July 12 at 8:23 PM
AMD Ryzen PRO Desktop Processors Deliver Professional-Grade Performance, Security, and Reliability for ... - NasdaqAMD Ryzen PRO Desktop Processors Deliver Professional-Grade Performance, Security, and Reliability for ... - Nasdaq
www.nasdaq.com - June 30 at 1:23 AM
Verseon presents data on DME program at BIO 2017 - London South East (registration) (blog)Verseon presents data on DME program at BIO 2017 - London South East (registration) (blog)
www.lse.co.uk - June 26 at 3:33 PM
Verseon to present drug programs at BIO 2017 - London South East (registration) (blog)Verseon to present drug programs at BIO 2017 - London South East (registration) (blog)
www.lse.co.uk - June 13 at 9:06 AM

SEC Filings

Verseon (LON:VSN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Verseon (LON VSN) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.